Preclinical News and Research

RSS
Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

OrPro to advance development of ORP-100 for treatment of cystic fibrosis

OrPro to advance development of ORP-100 for treatment of cystic fibrosis

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

NIDA announces 2012 recipient of Avant-Garde Award for Medications Development

NIDA announces 2012 recipient of Avant-Garde Award for Medications Development

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

Merck signs two licensing agreements for investigational HIV drug candidates

Merck signs two licensing agreements for investigational HIV drug candidates

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Novel combination drug regimen could be more effective than existing treatments for TB

Novel combination drug regimen could be more effective than existing treatments for TB

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

TB combination drug trials progress

TB combination drug trials progress

New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

FDA meeting confirms Orexo regulatory submission of OX219 NDA on track

FDA meeting confirms Orexo regulatory submission of OX219 NDA on track

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Researchers identify several gene mutations responsible for medulloblastoma

Researchers identify several gene mutations responsible for medulloblastoma

BioDiem presents positive findings of their eye disease drug at international conference

BioDiem presents positive findings of their eye disease drug at international conference

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.